2018
Changes in alcohol use associated with changes in HIV disease severity over time: A national longitudinal study in the Veterans Aging Cohort
Williams EC, McGinnis KA, Bobb JF, Rubinsky AD, Lapham GT, Skanderson M, Catz SL, Bensley KM, Richards JE, Bryant KJ, Edelman EJ, Satre DD, Marshall BDL, Kraemer KL, Blosnich JR, Crystal S, Gordon AJ, Fiellin DA, Justice AC, Bradley KA. Changes in alcohol use associated with changes in HIV disease severity over time: A national longitudinal study in the Veterans Aging Cohort. Drug And Alcohol Dependence 2018, 189: 21-29. PMID: 29859388, PMCID: PMC6344121, DOI: 10.1016/j.drugalcdep.2018.04.022.Peer-Reviewed Original ResearchConceptsHIV severityAUDIT-C screensViral loadAlcohol useVeterans Aging Cohort Study (VACS) dataPoor HIV controlVeterans Aging CohortHIV disease severityAUDIT-C scoresCohort study dataLow-level drinkingStable drinkingVL analysisHIV controlMean changeAging CohortDisease severityPLWHGreater riskCD4Individual alcohol useSeverityDrinking trajectoriesNational Longitudinal StudyLongitudinal study
2016
Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes
Cain LE, Caniglia EC, Phillips A, Olson A, Muga R, Pérez-Hoyos S, Abgrall S, Costagliola D, Rubio R, Jarrín I, Bucher H, Fehr J, van Sighem A, Reiss P, Dabis F, Vandenhende MA, Logan R, Robins J, Sterne JAC, Justice A, Tate J, Touloumi G, Paparizos V, Esteve A, Casabona J, Seng R, Meyer L, Jose S, Sabin C, Hernán MA. Efavirenz versus boosted atazanavir-containing regimens and immunologic, virologic, and clinical outcomes. Medicine 2016, 95: e5133. PMID: 27741139, PMCID: PMC5072966, DOI: 10.1097/md.0000000000005133.Peer-Reviewed Original ResearchConceptsCD4 cell countEfavirenz regimenVirologic failureVirologic outcomesSurvival differencesNucleoside reverse transcriptase inhibitor (NRTI) backboneCell countReverse transcriptase inhibitor backboneAtazanavir-containing regimensAIDS-free survivalHuman immunodeficiency virusImmune deficiency syndromeHIV-CAUSAL CollaborationAtazanavir regimenHazard ratioClinical outcomesImmunodeficiency virusProspective studyDeficiency syndromeMean changeRegimensEfavirenzTime-varying covariatesInhibitor backboneRegimen